A method to analyze nucleic acid(s) defining gene(s) exhibiting altered expression by schizophrenia
CA 2454700 A1 · Owner: Iritani, Shuji · Inventors: Takahashi, Hitoshi; Iritani, Shuji; Nawa, Hiroyuki
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
To contribute to objective diagnosis of schizophrenia with the use of gene expression as an indication, it is intended to provide a method of analyzing whether or not the expression dose of a nucleic acid specifying a gene showing a change in the expression dose in a subjects with schizophrenia statistically falls within the range of the expression dose of normal subjects. This method is characterized by involving the step of quantifying the expression dose of a nucleic acid specifying a gene showing a change in its expression dose due to schizophrenia and/or the expression dose of a protein encoded by the above nucleic acid specifying a gene showing a change in its expression dose …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 15, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 15, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 15, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.